← Back to Search

Radiopharmaceutical

Single arm for Amyloidosis (AT01-001 Trial)

Phase 2

Waitlist Available

Research Sponsored by Attralus, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up visit 2 (week 6) and safety follow-up 2 at 28 days following the second infusion at week 6.

Awards & highlights

AT01-001 Trial Summary

This trial will study how well AT-01 works in people with amyloidosis.

AT01-001 Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ visit 2 (week 6) and safety follow-up 2 at 28 days following the second infusion at week 6.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~visit 2 (week 6) and safety follow-up 2 at 28 days following the second infusion at week 6.

This trial's timeline: 3 weeks for screening, Varies for treatment, and visit 2 (week 6) and safety follow-up 2 at 28 days following the second infusion at week 6. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Repeatability of organ specific quantitation of radiotracer uptake at baseline and 6 weeks.

Secondary outcome measures

Change from Baseline in anti-drug antibody (ADA).

Incidence of treatment-emergent adverse events [safety and tolerability]

Number of participants with abnormal hematology and chemistry laboratory test results.

+1 more

AT01-001 Trial Design

1Treatment groups

Experimental Treatment

Group I: Single armExperimental Treatment1 Intervention

I-124 AT-01

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Attralus, Inc.Lead Sponsor

6 Previous Clinical Trials

323 Total Patients Enrolled

6 Trials studying Amyloidosis

323 Patients Enrolled for Amyloidosis

Gregory M. Bell, MDStudy DirectorAttralus, Inc.

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Do you think this treatment plan is viable in the long-term?

"The Power team has evaluated the safety of this treatment to be a 2. This is because, as it is a Phase 2 trial, while there is some data supporting safety, there is none yet for efficacy."

Answered by AI

Are we still enrolling patients for this trial?

"Unfortunately, this particular trial is not currently looking for patients. The listing on clinicaltrials.gov reveals that the last edit was on September 12th, 2022 and the original posting was on November 30th, 2021. Although this study isn't taking any more participants, there are 98 other trials with open recruitment at this time."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic Amyloidosis

2021. "A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic Amyloidosis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05235269.

All > Amyloidosis